Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to refer the Impact Assessment for the 2023 Statutory Scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.

There are no plans to refer the statutory scheme Impact Assessment to the Regulatory Policy Committee. The proposals only impact companies which choose to sell to the National Health Service and are therefore considered to be in connection with procurement. Given this, the statutory exclusion from the Better Regulation Framework “Procurement 22(4)(b)” applies as confirmed previously by the Economic and Domestic Affairs Secretariat at the Cabinet Office.